High‐dose intravenous desferrioxamine (DFO) delivery in four thalassemic patients allergic to subcutaneous DFO administration

No abstract is available for this paper.

• Publication year

  1996

• Venue

  American journal of hematology/oncology

• Publication date

  1996-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/(SICI)1096-8652(199601)51:1<90::AID-AJH15>3.0.CO;2-FPMID 8571945
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Long-term intravenous deferoxamine treatment for noncompliant transfusion-dependent beta-thalassemia patients.

  1994cited by this paper
• [Intensifying iron chelating therapy with desferrioxamine using implantable venous access catheters (Port-A-Cath)].

  1992cited by this paper
• Novel delivery system for continuous desferrioxamine infusion in iron-overloaded patients.

  1992cited by this paper
• Desferal (desferrioxamine)--a novel activator of connective tissue-type mast cells.

  1991cited by this paper
• Treatment of chronic iron overload.

  1991cited by this paper
• Treatment of chronic iron overload.

  1991cited by this paper
• Current status of iron chelation therapy with deferoxamine.

  1990cited by this paper
• Survival and causes of death in thalassaemia major.

  1989cited by this paper
• Rapid removal of excessive iron with daily, high-dose intravenous chelation therapy.

  1989cited by this paper
• Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major.

  1985cited by this paper
• Rapid desensitisation for desferrioxamine anaphylactoid reaction.

  1983cited by this paper
• RAPID DESENSITISATION FOR DESFERRIOXAMINE ANAPHYLACTOID REACTIONS

  1983cited by this paper
• Letter: Fenestrated tracheostomy tubes.

  1973cited by this paper

• First Case Report of Deferiprone-Induced Anaphylactic Reaction

  2024cites this paper
• First Case Report of Deferiprone Induced Anaphylaxis Reaction

  2024cites this paper
• Challenges of Iron Chelation in Thalassemic Children

  2024cites this paper
• Nutrition in chronic inflammatory conditions: Bypassing the mucosal block for micronutrients

  2023cites this paper
• Use of Drug challenge in a Case of Possible Deferoxamine Allergy.

  2019cites this paper
• Safety profiles of iron chelators in young patients with haemoglobinopathies

  2017cites this paper
• Protective effect of Clerodendrum colebrookianum leaves against iron-induced oxidative stress and hepatotoxicity in Swiss albino mice.

  2015cites this paper
• From the American Heart Association -Thalassemia Major: A Consensus Statement β Cardiovascular Function and Treatment in

  2014cites this paper
• Comparison of Deferoxamine, Activated Charcoal, and Vitamin C in Changing the Serum Level of Fe in Iron Overloaded Rats

  2014cites this paper
• Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart Association.

  2013cites this paper
• Iron Supplementation Decreases Severity of Allergic Inflammation in Murine Lung

  2012cites this paper
• AHA Consensus Statement

  2011cites this paper
• Ultrasensitive detection of ferritin in human serum by Western blotting based on quantum dots‐labeled avidin–biotin system

  2011cites this paper
• Disorders of Hemoglobin: THE β THALASSEMIAS

  2009cites this paper
• The molecular mechanisms of iron and ferritin metabolism in.

  2008influential citation
• Iron Storage Disorders

  2007cites this paper
• Deferoxamine synergistically enhances iron-mediated AP-1 activation: A showcase of the interplay between extracellular-signal-regulated kinase and tyrosine phosphatase

  2007cites this paper
• Weekend Very High-dose Intravenous Deferoxamine in Children With Transfusional Iron Overload

  2006cites this paper
• The effect of new lipophilic chelators on the activities of cytosolic reductases and P450 cytochromes involved in the metabolism of anthracycline antibiotics: studies in vitro.

  2004cites this paper
• Iron chelators for the treatment of iron overload disease: Relationship between structure, redox activity, and toxicity

  2003cites this paper
• Interactions of the pyridine-2-carboxaldehyde isonicotinoyl hydrazone class of chelators with iron and DNA: implications for toxicity in the treatment of iron overload disease

  2003cites this paper
• Orally active iron chelators.

  2002cites this paper
• HBED ligand: preclinical studies of a potential alternative to deferoxamine for treatment of chronic iron overload and acute iron poisoning.

  2002cites this paper
• Iron chelation therapy

  2000cites this paper
• Subcutaneous bolus injection of deferoxamine in adult patients affected by onco-hematologic diseases and iron overload.

  1998cites this paper
• 5 Thalassaemia: clinical management

  1998cites this paper
• Thalassaemia: clinical management.

  1998cites this paper
• Development of iron chelators to treat iron overload disease and their use as experimental tools to probe intracellular iron metabolism

  1998cites this paper
• Iron Chelators for Thalassaemia

  1998cites this paper
• Continuous low-dose subcutaneous desferrioxamine (DFO) to prevent allergic manifestations in patients with iron overload

  1996cites this paper